Simcyp Releases Version 12 of its Simulator, Extending its Lead in the Application of Population-Based Modelling and Simulation

Simcyp Releases Version 12 of its Simulator, Extending its Lead in the Application of Population-Based Modelling and Simulation

<0> SimcypElizabeth KingsleyEmail: Phone: +44 (0)114 292 2337 </0>

Simcyp, now part of Certara, is pleased to announce the release of Version 12 of its Population-based Simulator, the pharmaceutical industry's most sophisticated platform for the quantitative prediction of drug-drug interactions and pharmacokinetic-pharmacodynamic outcomes in both healthy subjects and diverse patient populations.

Version 12 extends Simcyp's lead in its recognised field of expertise with the implementation of a mechanistic kidney model, expanded drug distribution models, and enhancements and additions to its extensive compound libraries and paediatric module. Also, the incorporation of physiologically-based pharmacokinetic (PBPK) models for therapeutic proteins propagates the utility of the Simcyp Simulator into the development of biologics.

Simcyp's focus on cutting-edge research sets the standard amongst modelling and simulation providers. In this respect, the Simcyp approach continues to be enhanced by the commission of academic research projects to fill knowledge gaps impeding progress in the application of PBPK modelling, such as those related to transporter abundances and associated scaling factors.

Commenting on the release, Professor Amin Rostami, VP Research and Development, Simcyp, said:

Professor Geoff Tucker, VP Translational Science at Certara and Head of Simcyp Consultancy, commented:

Version 12 of the Simcyp Simulator is now available to all Consortium Members and academic associates with current not-for-profit license agreements.

– ENDS –

Simcyp provides platforms for the modelling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals (rat, dog & mouse). The technology allows pharmaceutical researchers to predict outcomes from routinely generated data, to fit Simcyp models to observed clinical data and to assess inter-individual variability through 'real-life' simulations. Simcyp also runs educational workshops and provides strategic consultancy in drug development. For more information, visit

Certara is dedicated to improving human health through a broad spectrum of software products and consulting services that enable model-based drug development. Certara was formed by uniting industry leaders Tripos®, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery; Simcyp®, a research-based company providing predictive pharmacokinetic and pharmacodynamics tools, workshops, and consultancy services; and Pharsight® Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development.

Each Certara family brand has a primary focus and expertise in enabling model-based drug development in a key phase within the drug discovery and development process; combined, they offer a unique set of capabilities for modeling, analysis, and simulation with scientific informatics that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit .

Representatives from Simcyp are available on request.

Notes:

Suggested Articles

Former Ipsen and Novartis exec Harout Semerjian has been tapped as the latest chief executive of troubled Immunomedics.

A COVID-19 vaccine developed by a Mass General spinoff is among the candidates emerging from partnerships between tech developers and bio researchers.

Vir and GlaxoSmithKline will pool their resources to develop vaccines and treatments for coronaviruses, starting with two antibodies against COVID-19.